EGFR and non-small cell lung carcinoma: However, understanding the molecular underpinnings of NSCLC led to the development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), dramatically improving treatment outcomes compared to chemotherapy [4,5,6,7,8,9].